Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
Three-dimensional (3D) bioprinting utilises printing techniques to combine cells, growth media and/or biomaterials to produce 3D bio-tissues, with the aim of imitating natural tissue characteristics. Fields in which 3D bioprinting could be used include tissue engineering, regenerative medicine, drug toxicology screening, clinical transplantation, high-throughput assays, and cancer research.
The initial brief of the executive will be to:
(1) Phase 1 - Provide a market assessment/evaluation and present a recommendation for launch and go-to-market strategy for company
(2) Produce a viable 5 year business plan;
(3) Obtain university approval for the venture;
(4) a. Act for the company in the spin-out legal process and address all company formation matters;
b. Obtain founder academics and Newcastle University (including the Head of Company Creation) approval for appointment as CEO.
c. Provide to the appropriate university all matters necessary for Research England reporting requirements;
(5) Secure (venture capital and other) funding
| Supplier | Identifier | Award Value | Cross-References |
|---|---|---|---|
| IVO Associates | - | £28,900 | - |